| Property | Value |
|---|
|
?:abstract
|
-
Given the very recent development of infection in humans by SARS coronavirus 2 in the world, there is not yet accepted guidelines for its treatment In the vast majority of the patients the infection produces mild symptoms and can even be completely asymptomatic In a small minority of the patients, the infection and result in progressive respiratory distress and multiorgan failure Isolation of infected individuals to decrease the transmission of the disease in the general population and in the personnel who provide treatment to the patients is essential Several treatments have been suggested, but up to now none of them have had clearly positive results Remdesivir, a drug developed for the treatment of Ebola, seems to offer the best possibilities Prophylactic anticoagulation has been recommended, as a large number of patients suffers from abnormal coagulation A syndrome similar to Kawasaki disease has been described in children and adolescents either during the period of disease or during convalescence
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
-
Acta_Pediatrica_De_Mexico
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
SARS-CoV-2 infection. Guidelines on treatment
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}